comparemela.com

Latest Breaking News On - Salvatore pece - Page 1 : comparemela.com

Tiziana Life Sciences Ltd : StemPrintER Demonstrates Prognostic Utility in TransATAC Cohort

NEW YORK, March 01, 2022 (GLOBE NEWSWIRE) Tiziana Life Sciences Ltd.'s (Nasdaq: TLSA) former subsidiary, AccuStem Sciences, Inc. (OTC PINK: ACMSY) (formerly AccuStem Sciences Ltd.), today announced

City ofUnited kingdomIrina kofflerHana malikMilan university medical schoolLifesci advisorsStem cell pathobiology labAccustem sciences incTiziana life sciences ltdAccustem sciences ltdEuropean institute of oncologyBusiness developmentLife sciencesAccustem sciencesEuropean journalEuropean institute

AccuStem s StemPrintER Demonstrates Prognostic Utility in TransATAC Cohort | Your Money

LONDON and PHOENIX, March 01, 2022 (GLOBE NEWSWIRE) AccuStem Sciences, Inc. (OTC PINK: ACMSY), a life sciences company dedicated to improving outcomes for patients with cancer, today announced publication

United statesCity ofUnited kingdomMilan university medical schoolStem cell pathobiology labAccustem sciences incEuropean society of breast cancer specialistsEuropean institute of oncologyEuropean organisation for researchStem sciencesEuropean journalEuropean instituteRoyal marsden hospitalBreast cancerSalvatore peceFull professor

Tiziana Life Sciences : StemPrintER Demonstrates Prognostic Utility in TransATAC Cohort

New York, March 1, 2022 - Tiziana Life Sciences Ltd. reports that its former subsidiary, AccuStem Sciences, Inc. , today announced publication of new data in the European Journal of Cancer.. | March 1, 2022

New yorkUnited statesCity ofUnited kingdomIrina kofflerHana malikMilan university medical schoolLifesci advisorsEuropean organisation for researchTiziana life sciencesStem cell pathobiology labAccustem sciences incEuropean society of breast cancer specialistsTiziana life sciences ltdAccustem sciences ltdEuropean institute of oncology

Accustem Sciences, Inc: AccuStem s StemPrintER Demonstrates Prognostic Utility in TransATAC Cohort

LONDON and PHOENIX, March 01, 2022 (GLOBE NEWSWIRE) AccuStem Sciences, Inc. (OTC PINK: ACMSY), a life sciences company dedicated to improving outcomes for patients with cancer, today announced publication

United statesCity ofUnited kingdomMilan university medical schoolStem cell pathobiology labAccustem sciences incEuropean institute of oncologyStem sciencesEuropean journalEuropean instituteRoyal marsden hospitalBreast cancerSalvatore peceFull professorHormone related cancersAccustem sciences

vimarsana © 2020. All Rights Reserved.